Cell therapy for osteonecrosis of femoral head and joint preservation

You Seung Chun; Dong Hwan Lee; Tae Gu Won; Chan Sik Kim; Asode Ananthram Shetty; Seok Jung Kim

doi:10.1016/j.jcot.2021.101713

Cell therapy for osteonecrosis of femoral head and joint preservation

J Clin Orthop Trauma. 2021 Nov 27:24:101713. doi: 10.1016/j.jcot.2021.101713. eCollection 2022 Jan.

Authors

You Seung Chun¹, Dong Hwan Lee¹, Tae Gu Won¹, Chan Sik Kim¹, Asode Ananthram Shetty², Seok Jung Kim¹

Affiliations

¹ Department of Orthopedic Surgery, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
² Canterbury Christ Church University, Faculty of Medicine, Health and Social Care, 30 Pembroke Court, Chatham Maritime, Kent, ME4 4UF, United Kingdom.

Abstract

Osteonecrosis of femoral head (ONFH) is a disease of the femoral head and can cause femoral head collapse and arthritis. This can lead to pain and gait disorders. ONFH has various risk factors, it is often progressive, and if untreated results in secondary osteo-arthritis. Biological therapy makes use of bone marrow concentrate, cultured osteoblast and mesenchymal stem cell (MSC) obtained from various sources. These are often used in conjunction with core decompression surgery. In this review article, we discuss the current status of cell therapy and its limitations. We also present the future development of biological approach to treat ONFH.

Keywords: Cell therapy; Core decompression; Femoral head; Osteonecrosis; Pathogenesis; Stem cell.